Pediatrix Q2 Earnings Beat with $0.63 Adjusted EPS; Reaffirms 2026 EBITDA Guidance
MD has more than doubled off its 52-week low of $11.84.
Summary
Pediatrix Medical Group reported Q2 2026 Adjusted EPS of $0.63, beating estimates, and reaffirmed its full-year Adjusted EBITDA guidance of $280–$300 million. Revenue rose 4% to $488 million, and the company bought back $42.7 million in shares.
Key Events · Earnings and Guidance · MD
-
Q2 Earnings Beat
Adjusted EPS of $0.63 exceeded expectations; net revenue rose 4% YoY to $487.8 million, driven by acquisitions and favorable reimbursement trends.
-
Guidance Reaffirmed
Full-year 2026 Adjusted EBITDA guidance maintained at $280–$300 million, consistent with prior outlook.
-
Strong Balance Sheet
Cash and equivalents of $288.9 million at quarter-end; total debt of $584 million with no borrowings under the $450 million revolver.
-
Aggressive Buybacks Continue
Repurchased $42.7 million in shares during Q2, reducing weighted average diluted shares to 81.4 million from 85.5 million a year ago.
Analysis · MD · Industrial Applications And Services
Pediatrix delivered a solid quarter with Adjusted EPS of $0.63, beating expectations, and reaffirmed its full-year Adjusted EBITDA outlook of $280–$300 million. Revenue grew 4% year-over-year to $488 million, driven by acquisitions and improved reimbursement. The company continued aggressive share buybacks, repurchasing $42.7 million in stock during the quarter, which helped lift EPS. With $289 million in cash and no revolver borrowings, the balance sheet remains strong, supporting both organic growth and potential strategic moves.
At the time of this filing, MD was trading at $25.68 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $11.84 to $27.94. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.